Posted by Michael Wonder on 29 Apr 2022
U.S. Food and Drug Administration approves Camzyos (mavacamten) for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms
28 April 2022 - Camzyos is the first and only FDA approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM.
Bristol Myers Squibb today announced that the U.S FDA approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
